Aug 12, 2026 04:01PM

May 11, 2026 04:01PM

May 7, 2026 08:04AM

May 7, 2026 08:00AM

Mar 17, 2026 05:00PM

Mar 5, 2026 04:01PM

Dec 22, 2025 08:00AM ArriVent begins phase 3 trial for lung cancer drug firmonertinib

Dec 22, 2025 08:00AM

Nov 10, 2025 08:00AM

Sep 9, 2025 08:00AM

Sep 9, 2025 08:00AM

Aug 11, 2025 08:00AM

Jul 21, 2025 08:01AM

Jul 21, 2025 08:00AM ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

May 14, 2025 07:52AM

May 12, 2025 08:00AM

Mar 7, 2025 06:42AM

Mar 3, 2025 07:00AM

Nov 14, 2024 08:00AM

Sep 9, 2024 12:07PM

Sep 9, 2024 12:05PM ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung C

Mar 28, 2024 08:30PM

Mar 28, 2024 04:05PM

Jan 5, 2024 04:20PM

329,975 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All